U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Gemifloxacin – Oral Products
  1. Development Resources

Gemifloxacin – Oral Products

Recognized Interpretive Criteria

 

Minimum Inhibitory
Concentrations

(mcg/mL)

Disk Diffusion
(zone diameter in mm)

Pathogen

S

I

R

S

I

R

Enterobacterales

M100 standard is recognized

Haemophilus influenzae and parainfluenzae

M100 standard is recognized

Streptococcus pneumoniae

M100 standard is recognized

S = Susceptible; I = Intermediate; R = Resistant

Back to Top